Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2017138983) THERAPEUTIC NANOPARTICLES HAVING EGFR LIGANDS AND METHODS OF MAKING AND USING SAME
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2017/138983 International Application No.: PCT/US2016/047807
Publication Date: 17.08.2017 International Filing Date: 19.08.2016
IPC:
A61K 49/08 (2006.01) ,A61K 51/08 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
49
Preparations for testing in vivo
06
Nuclear magnetic resonance (NMR) contrast preparations; Magnetic resonance imaging (MRI) contrast preparations
08
characterised by the carrier
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
51
Preparations containing radioactive substances for use in therapy or testing in vivo
02
characterised by the carrier
04
Organic compounds
08
Peptides, e.g. proteins
Applicants:
PFIZER INC. [US/US]; 235 East 42nd Street New York, NY 10017, US
Inventors:
ZALE, Stephen, E.; US
MCDONNELL, Kevin; US
HORHOTA, Allen; US
Agent:
ZIELINSKI, Bryan C.; US
Priority Data:
62/293,60910.02.2016US
62/369,59001.08.2016US
Title (EN) THERAPEUTIC NANOPARTICLES HAVING EGFR LIGANDS AND METHODS OF MAKING AND USING SAME
(FR) NANOPARTICULES THÉRAPEUTIQUES COMPRENANT DES LIGANDS EGFR ET LEURS PROCÉDÉS DE PRODUCTION ET D'UTILISATION
Abstract:
(EN) Provided herein in part is a therapeutic nanoparticle that includes a biocompatible polymer; a polymer -EGFR ligand conjugate, wherein the EGFR ligand is covalently bound directly or through a chemical linker to the polymer, and a therapeutic agent.
(FR) L'invention concerne en partie une nanoparticule thérapeutique qui comprend un polymère biocompatible; un conjugué polymère-ligand EGFR dans lequel le ligand EGFR est lié par liaison covalente directement au polymère ou par l'intermédiaire d'un coupleur chimique, et un agent thérapeutique.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
AU2016392719CA3013896CN108697815EP3413917